Molecular Financial Statements From 2010 to 2026

MOLN Stock  USD 4.25  0.01  0.23%   
Molecular Partners' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Molecular Partners' valuation are provided below:
Gross Profit
-40.4 M
Market Capitalization
158.9 M
Enterprise Value Revenue
3.8144
Earnings Share
(2.03)
Quarterly Revenue Growth
(1.00)
We have found one hundred twenty available fundamental ratios for Molecular Partners, which can be analyzed and compared to other ratios and to its peers in the industry. Self-guided Investors are advised to check Molecular Partners' last-minute fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 10th of January 2026, Market Cap is likely to drop to about 151 M. In addition to that, Enterprise Value is likely to drop to about 83.8 M

Molecular Partners Total Revenue

5.43 Million

Check Molecular Partners financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Molecular Partners' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.9 M, Interest Expense of 27.3 K or Selling General Administrative of 12.7 M, as well as many indicators such as Price To Sales Ratio of 20.99, Dividend Yield of 0.0 or PTB Ratio of 1.07. Molecular financial statements analysis is a perfect complement when working with Molecular Partners Valuation or Volatility modules.
  
Build AI portfolio with Molecular Stock
Check out the analysis of Molecular Partners Correlation against competitors.

Molecular Partners Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets191.7 M182.3 M164.5 M
Slightly volatile
Other Current Liabilities9.4 M10.2 M7.9 M
Slightly volatile
Total Current Liabilities11.8 M12.4 M23.9 M
Pretty Stable
Total Stockholder Equity138.8 M162.9 M115.4 M
Slightly volatile
Property Plant And Equipment Net4.7 M4.8 MM
Slightly volatile
Current Deferred Revenue3.7 M3.9 M16 M
Slightly volatile
Accounts Payable741.8 K780.9 K1.2 M
Slightly volatile
Cash90.7 M57.5 M105.7 M
Slightly volatile
Non Current Assets TotalM4.9 M4.2 M
Slightly volatile
Cash And Short Term Investments174.8 M171.9 M149.5 M
Slightly volatile
Net Receivables244.5 K257.4 K8.2 M
Pretty Stable
Common Stock Total Equity2.3 M3.4 M2.3 M
Slightly volatile
Common Stock Shares Outstanding27 M39.1 M24.6 M
Slightly volatile
Liabilities And Stockholders Equity191.7 M182.3 M164.5 M
Slightly volatile
Non Current Liabilities Total5.2 M5.5 M23 M
Slightly volatile
Other Current Assets5.5 M5.2 M2.1 M
Slightly volatile
Other Stockholder Equity262.5 M441.5 M220.6 M
Slightly volatile
Total Liabilities14.4 M15.2 M46.6 M
Slightly volatile
Property Plant And Equipment Gross27.1 M25.8 M10.2 M
Slightly volatile
Total Current Assets186.8 M177.4 M160.3 M
Slightly volatile
Short Term Debt1.4 M1.1 MM
Slightly volatile
Intangible Assets53.5 K56.4 K157.8 K
Slightly volatile
Common Stock2.9 M4.6 M2.5 M
Slightly volatile
Other Liabilities5.3 M5.6 M12.7 M
Slightly volatile
Net Tangible Assets283.6 M270.1 M150 M
Slightly volatile
Net Invested Capital141.7 M162.9 M126.6 M
Slightly volatile
Net Working Capital153 M165 M137 M
Slightly volatile
Property Plant Equipment5.9 M8.3 M4.4 M
Slightly volatile
Capital Stock3.4 M4.6 M2.7 M
Slightly volatile
Short and Long Term Debt Total3.6 M2.2 M3.3 M
Slightly volatile
Other AssetsM4.6 MM
Slightly volatile
Capital Lease Obligations3.6 M2.2 M3.3 M
Slightly volatile

Molecular Partners Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.9 M2.7 M1.6 M
Slightly volatile
Interest Expense27.3 K28.8 K140.4 K
Slightly volatile
Selling General Administrative12.7 M19.7 M10.7 M
Slightly volatile
Selling And Marketing Expenses48.7 K51.3 K1.9 M
Pretty Stable
Total Revenue5.4 M5.7 M28.9 M
Very volatile
Other Operating Expenses57 M76.1 M48.9 M
Slightly volatile
Research Development43.8 M55.9 M37.6 M
Slightly volatile
Cost Of Revenue32.3 M54.6 M26 M
Slightly volatile
Total Operating Expenses20.4 M21.5 M37.9 M
Pretty Stable
Interest Income4.1 M3.9 M1.4 M
Slightly volatile
Reconciled Depreciation2.4 M2.7 M1.8 M
Slightly volatile

Molecular Partners Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation3.7 M4.7 MM
Slightly volatile
Begin Period Cash Flow94 M60.6 M112 M
Slightly volatile
Depreciation1.9 M2.7 M1.6 M
Slightly volatile
Capital Expenditures896 K650.7 K1.1 M
Slightly volatile
End Period Cash Flow90.7 M57.5 M105.7 M
Slightly volatile
Dividends Paid200 K225 K245.6 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio20.9925.0223.64
Slightly volatile
PTB Ratio1.071.124.5695
Slightly volatile
Days Sales Outstanding69.6473.3230
Very volatile
Book Value Per Share5.834.794.8061
Pretty Stable
Average Payables630 K708.7 K773.6 K
Slightly volatile
Stock Based Compensation To Revenue0.780.740.2919
Slightly volatile
Capex To Depreciation0.330.350.9224
Slightly volatile
PB Ratio1.071.124.5695
Slightly volatile
EV To Sales15.313.917.1051
Pretty Stable
Payables Turnover66.1162.9728.6859
Slightly volatile
Sales General And Administrative To Revenue3.263.111.1034
Slightly volatile
Average Inventory177.2 K227.8 K228.5 K
Slightly volatile
Research And Ddevelopement To Revenue9.248.83.5476
Slightly volatile
Capex To Revenue0.140.130.0778
Slightly volatile
Cash Per Share7.525.056.4354
Pretty Stable
Days Payables Outstanding5.76.093.8592
Slightly volatile
Intangibles To Total Assets3.0E-43.0E-40.0011
Pretty Stable
Current Ratio6.6612.877.8607
Slightly volatile
Tangible Book Value Per Share5.834.784.7992
Pretty Stable
Receivables Turnover3.834.0313.339
Pretty Stable
Shareholders Equity Per Share5.834.794.8061
Pretty Stable
Debt To Equity0.01890.01980.0406
Slightly volatile
Capex Per Share0.02320.02440.0503
Slightly volatile
Graham Net Net5.424.514.4548
Pretty Stable
Revenue Per Share0.160.171.2133
Pretty Stable
Interest Debt Per Share0.06790.06560.0678
Slightly volatile
Debt To Assets0.02750.01770.0243
Pretty Stable
Graham Number11.5421.8918.767
Slightly volatile
Price Book Value Ratio1.071.124.5695
Slightly volatile
Days Of Payables Outstanding5.76.093.8592
Slightly volatile
Company Equity Multiplier1.651.291.6323
Slightly volatile
Total Debt To Capitalization0.01850.01950.0389
Slightly volatile
Debt Equity Ratio0.01890.01980.0406
Slightly volatile
Quick Ratio6.712.877.9059
Slightly volatile
Net Income Per E B T1.11.151.015
Slightly volatile
Cash Ratio5.856.815.2432
Very volatile
Days Of Sales Outstanding69.6473.3230
Very volatile
Free Cash Flow Operating Cash Flow Ratio0.920.911.1163
Very volatile
Price To Book Ratio1.071.124.5695
Slightly volatile
Fixed Asset Turnover1.291.368.6101
Slightly volatile
Debt Ratio0.02750.01770.0243
Pretty Stable
Price Sales Ratio20.9925.0223.64
Slightly volatile
Asset Turnover0.03430.03610.1727
Slightly volatile
Price Fair Value1.071.124.5695
Slightly volatile

Molecular Partners Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap151 M158.9 M381.3 M
Slightly volatile
Enterprise Value83.8 M88.3 M284.5 M
Slightly volatile

Molecular Fundamental Market Drivers

Forward Price Earnings1.7775
Cash And Short Term Investments149.4 M

Molecular Upcoming Events

14th of March 2024
Upcoming Quarterly Report
View
10th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Molecular Partners Financial Statements

Molecular Partners investors utilize fundamental indicators, such as revenue or net income, to predict how Molecular Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue3.9 M3.7 M
Total Revenue5.7 M5.4 M
Cost Of Revenue54.6 M32.3 M
Stock Based Compensation To Revenue 0.74  0.78 
Sales General And Administrative To Revenue 3.11  3.26 
Research And Ddevelopement To Revenue 8.80  9.24 
Capex To Revenue 0.13  0.14 
Revenue Per Share 0.17  0.16 
Ebit Per Revenue(14.16)(13.46)

Pair Trading with Molecular Partners

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Molecular Partners position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will appreciate offsetting losses from the drop in the long position's value.

Moving together with Molecular Stock

  0.71AMGN Amgen IncPairCorr

Moving against Molecular Stock

  0.68LIPO Lipella PharmaceuticalsPairCorr
  0.67HPQ HP IncPairCorr
  0.67HD Home DepotPairCorr
The ability to find closely correlated positions to Molecular Partners could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Molecular Partners when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Molecular Partners - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Molecular Partners AG to buy it.
The correlation of Molecular Partners is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Molecular Partners moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Molecular Partners moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Molecular Partners can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Molecular Partners offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Molecular Partners' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Molecular Partners Ag Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Molecular Partners Ag Stock:
Check out the analysis of Molecular Partners Correlation against competitors.
You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Partners. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Partners listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.03)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.27)
Return On Equity
(0.51)
The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Molecular Partners' value and its price as these two are different measures arrived at by different means. Investors typically determine if Molecular Partners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Partners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.